Simvastatin cotreatment increases Cx‐43 levels and reduces Cx43 phosphorylation on Ser262 and Ser368 in human breast cancer cells, thus enhancing Doxorubicin cellular accumulation and cytotoxic effects. The gene discussed is GJA1; the disease is breast carcinoma.